Farah Rehman
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Farah Rehman has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
- Alessia Bertolotti
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
85 shared publications - Andrea Sottoriva
Computational Biology Research Centre, Human Technopole, Milan, Italy
85 shared publications - Andrea Vingiani
Oncology and Hematology-Oncology Department, School of Medicine, University of Milan, Milan, Italy; Department of Advanced Diagnostics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
85 shared publications - Balázs Győrffy
Semmelweis University
85 shared publications - Chela James
Human Technopole, Milan, Italy
85 shared publications - Chiara Ghirardi
Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy
85 shared publications
Latest Publications
- Open Access
- 27 October 2025
- Published by Wiley in The Journal of Pathology
- Vol. 268 (1) , 13-26
Identification of actionable targets using DEPArray ‐based sorting of pure carcinoma and stromal populations from formalin‐fixed paraffin‐embedded tissues followed by shallow whole‐genome sequencing
Formalin‐fixed paraffin‐embedded (FFPE) tissue specimens represent precious resources for clinical genomic profiling studies, especially when coupled with comprehensive medical records. Even though next‐generation sequencing (NGS) is an effective tool to detect somatic mutations and somatic copy number alterations (sCNA), the biggest challenges in unlocking clinically translatable genomic information from FFPE tissue are low DNA yields and degraded DNA, affected by variable formalin fixation. Another issue is that the proportion of carcinoma and other noncarcinoma cells is variable and can be confounded by intratumoral heterogeneity. To explore these challenges, we isolated pure carcinoma and stromal cells using the DEPArray™ NxT system, a microchip‐based digital sorter that allows isolation of pure, homogeneous subpopulations of cells from FFPE samples. We isolated pure carcinoma and stromal cell populations from 12 FFPE tissues, including tissues from nine primary and metastatic breast cancer and three primary ovarian high‐grade serous carcinomas. This was followed by downstream shallow whole‐genome sequencing (WGS) for copy number landscape profiling (10 samples) and/or a targeted panel for somatic mutation and sCNA analysis (seven samples), subject to cell availability. Seven out of 10 samples (even some with low tumour content or of old age) produced good‐quality genomic data, detecting sCNA in all carcinoma population samples but not in the stromal populations. Mutation analysis was performed successfully in 6/7 samples and somatic mutations were detected in all of them. Our workflow enabled the identification of clinically actionable targets, including PIK3CA, ERBB2, FGFR1/2, CDK6, CCNE1, KRAS amplifications and RB, BRCA1/2 losses in patients that would direct therapy. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- 27 October 2025
- Published by Wiley in The Journal of Pathology
- Vol. 268 (1) , 13-26
Open AccessIdentification of actionable targets using DEPArray ‐based sorting of pure carcinoma and stromal populations from formalin‐fixed paraffin‐embedded tissues followed by shallow whole‐genome sequencing
Formalin‐fixed paraffin‐embedded (FFPE) tissue specimens represent precious resources for clinical genomic profiling studies, especially when coupled with comprehensive medical records. Even though next‐generation sequencing (NGS) is an effective tool to detect somatic mutations and somatic copy number alterations (sCNA), the biggest challenges in unlocking clinically translatable genomic information from FFPE tissue are low DNA yields and degraded DNA, affected by variable formalin fixation. Another issue is that the proportion of carcinoma and other noncarcinoma cells is variable and can be confounded by intratumoral heterogeneity. To explore these challenges, we isolated pure carcinoma and stromal cells using the DEPArray™ NxT system, a microchip‐based digital sorter that allows isolation of pure, homogeneous subpopulations of cells from FFPE samples. We isolated pure carcinoma and stromal cell populations from 12 FFPE tissues, including tissues from nine primary and metastatic breast cancer and three primary ovarian high‐grade serous carcinomas. This was followed by downstream shallow whole‐genome sequencing (WGS) for copy number landscape profiling (10 samples) and/or a targeted panel for somatic mutation and sCNA analysis (seven samples), subject to cell availability. Seven out of 10 samples (even some with low tumour content or of old age) produced good‐quality genomic data, detecting sCNA in all carcinoma population samples but not in the stromal populations. Mutation analysis was performed successfully in 6/7 samples and somatic mutations were detected in all of them. Our workflow enabled the identification of clinically actionable targets, including PIK3CA, ERBB2, FGFR1/2, CDK6, CCNE1, KRAS amplifications and RB, BRCA1/2 losses in patients that would direct therapy. © 2025 The Author(s). The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
- Open Access
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300456
Serial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer
PURPOSE: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS: A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data. RESULTS: Personalized Signatera assays detected ctDNA ahead of clinical or radiologic relapse in 30 of the 34 patients who relapsed (patient-level sensitivity of 88.2%). Relapse was predicted with a lead interval of up to 38 months (median, 10.5 months; range, 0-38 months), and ctDNA positivity was associated with shorter relapse-free survival ( P < .0001) and overall survival ( P < .0001). All relapsing triple-negative patients (n = 7/23) had a ctDNA-positive test within a median of 8 months (range, 0-19 months), while the 16 nonrelapsed patients with triple-negative breast cancer remained ctDNA-negative during a median follow-up of 58 months (range, 8-99 months). The four patients who had negative tests before relapse all had hormone receptor–positive (HR+) disease and conversely, five of the 122 nonrelapsed patients (all HR+) had an occasional positive test. CONCLUSION: Serial postoperative ctDNA assessment has strong prognostic value, provides a potential window for earlier therapeutic intervention, and may enable more effective monitoring than current clinical tests such as cancer antigen 15-3. Our study provides evidence that those with serially negative ctDNA tests have superior clinical outcomes, providing reassurance to patients with breast cancer. For select cases with HR+ disease, decisions about treatment management might require serial monitoring despite the ctDNA-positive result.
- 1 December 2024
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 8 (8) , e2300456
Open AccessSerial Postoperative Circulating Tumor DNA Assessment Has Strong Prognostic Value During Long-Term Follow-Up in Patients With Breast Cancer
PURPOSE: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer. METHODS: A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data. RESULTS: Personalized Signatera assays detected ctDNA ahead of clinical or radiologic relapse in 30 of the 34 patients who relapsed (patient-level sensitivity of 88.2%). Relapse was predicted with a lead interval of up to 38 months (median, 10.5 months; range, 0-38 months), and ctDNA positivity was associated with shorter relapse-free survival ( P < .0001) and overall survival ( P < .0001). All relapsing triple-negative patients (n = 7/23) had a ctDNA-positive test within a median of 8 months (range, 0-19 months), while the 16 nonrelapsed patients with triple-negative breast cancer remained ctDNA-negative during a median follow-up of 58 months (range, 8-99 months). The four patients who had negative tests before relapse all had hormone receptor–positive (HR+) disease and conversely, five of the 122 nonrelapsed patients (all HR+) had an occasional positive test. CONCLUSION: Serial postoperative ctDNA assessment has strong prognostic value, provides a potential window for earlier therapeutic intervention, and may enable more effective monitoring than current clinical tests such as cancer antigen 15-3. Our study provides evidence that those with serially negative ctDNA tests have superior clinical outcomes, providing reassurance to patients with breast cancer. For select cases with HR+ disease, decisions about treatment management might require serial monitoring despite the ctDNA-positive result.
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Spatial transcriptomics of patient 1 (rare cohort treated with long-term ET until progression)
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Spatial transcriptomics of patient 1 (rare cohort treated with long-term ET until progression)
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Spatially resolved changes in the transcriptional profile of tumour-associated immune cells and stroma (Patient 1-3, rare cohort treated with long-term ET until progression)
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Spatially resolved changes in the transcriptional profile of tumour-associated immune cells and stroma (Patient 1-3, rare cohort treated with long-term ET until progression)
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Spatially resolved changes in the transcriptional profile of tumour-associated immune cells and stroma (Patient 1-3, rare cohort treated with long-term ET until progression)
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Spatially resolved changes in the transcriptional profile of tumour-associated immune cells and stroma (Patient 1-3, rare cohort treated with long-term ET until progression)
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Clinical history of patient 1 (rare cohort treated with long-term ET until progression)
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Clinical history of patient 1 (rare cohort treated with long-term ET until progression)
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Correlation between barcode composition in Traditiom samples
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Correlation between barcode composition in Traditiom samples
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S12 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
The de novo dormant persister pool is generated stochastically
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S12 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
The de novo dormant persister pool is generated stochastically
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Differentially expressed genes for MCF7: AI (-E2) latency and dormancy samples Vs POT; awakening Vs Dormancy samples
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Differentially expressed genes for MCF7: AI (-E2) latency and dormancy samples Vs POT; awakening Vs Dormancy samples
- Open Access
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 7 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Expression matrix for dormancy associated genes
- 1 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 7 from Long-term Multimodal Recording Reveals Epigenetic Adaptation Routes in Dormant Breast Cancer Cells
Expression matrix for dormancy associated genes